Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesWest Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
408.5 USD 8.69 ( 2.17%)
Last update at 2026-11-09T17:46:00Z
VOLUME
138454
Market Cap
25687.15M
P/E
46.73

Momentum Score

…

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
398.14
Low
409.01
High
52 Week Price Range
223.52
Low
385.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

West Pharmaceutical Services makes components and systems for injectable drug administration used by pharmaceutical and biotech companies; long-term growth may be supported by rising demand for biologics and injectable therapies, greater outsourcing of drug-device components, and expansion in emerging markets. Investors may find the company attractive for its specialized manufacturing capabilities and established regulatory-compliant supply footprint.
Material risks include customer concentration and dependence on pharmaceutical R&D and manufacturing spending, potential operational and supply-chain disruptions, and regulatory or quality-related issues that could affect production and approvals.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
399.81
Dividend Yield
0.24%
Revenue TTM
3326.80M
Revenue Per Share
46.30
Gross Profit TTM
1223.80M
Debt / Equity
0.13
ROE
19.09%
Net Debt
-374.60M
ROCE
16.57%
Diluted EPS TTM
7.81

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 615.30M 600.20M 715.70M 679.90M 748.90M
Net income 493.70M 492.70M 593.40M 585.90M 661.80M
Selling general administrative 388.70M 338.50M 353.40M 343.70M 362.80M
Gross profit 1103.30M 1002.20M 1132.70M 1136.20M 1175.80M
Reconciled depreciation 171.40M 155.40M 137.30M 120.60M 122.30M
Ebit 599.20M 588.40M 706.80M 734.00M 752.30M
Ebitda 723.60M 743.80M 844.10M 854.60M 878.40M
Depreciation and amortization 124.40M 155.40M 137.30M 120.60M 126.10M
Non operating income net other - - - -25.50M 24.90M
Operating income 617.40M 594.60M 710.90M 734.00M 752.30M
Other operating expenses 2456.30M 2298.10M 2240.20M 2152.90M 2079.30M
Interest expense 0.60M 2.90M 8.80M 7.90M 7.20M
Tax provision 121.60M 107.50M 122.30M 114.70M 107.20M
Interest income 17.00M 19.60M 28.00M 2.80M 7.20M
Net interest income 17.00M 16.60M 19.00M -2.80M -7.20M
Extraordinary items - - - 5.70M 1.40M
Income tax expense 121.60M 107.50M 122.30M 114.70M 107.20M
Total revenue 3073.70M 2892.70M 2951.10M 2886.90M 2831.60M
Total operating expenses 485.90M 407.60M 421.80M 402.20M 423.50M
Cost of revenue 1970.40M 1890.50M 1818.40M 1750.70M 1655.80M
Total other income expense net -2.10M 5.60M 4.80M -54.10M -3.40M
Net income from continuing ops 493.70M 492.70M 593.40M 565.20M 641.70M
Net income applicable to common shares 493.70M 492.70M 593.40M 585.90M 661.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4270.00M 3643.40M 3829.50M 3616.80M 3313.80M
Intangible assets 7.70M 10.80M 15.10M 18.40M 23.00M
Other current assets 168.60M 124.00M 135.80M 103.00M 112.00M
Total liab 1094.00M 961.10M 948.50M 931.90M 978.40M
Total stockholder equity 3176.00M 2682.30M 2881.00M 2684.90M 2335.40M
Deferred long term liab - - - 33.40M 33.80M
Other current liab 378.50M 192.40M 205.00M 228.10M 259.70M
Common stock 18.80M 18.80M 18.80M 18.80M 18.80M
Capital stock 18.80M 18.80M 18.80M 18.80M 18.80M
Retained earnings 4374.90M 3956.60M 3523.40M 2987.80M 2456.70M
Other liab - - - 113.20M 112.50M
Good will 110.00M 106.10M 108.50M 107.30M 109.90M
Other assets -0.10M -0.10M 47.00M 104.00M 104.40M
Cash 791.30M 484.60M 853.90M 894.30M 762.60M
Cash and equivalents 791.30M 484.60M 853.90M 894.30M 762.60M
Total current liabilities 654.90M 550.40M 671.80M 519.00M 594.10M
Current deferred revenue - 49.60M 41.70M 57.30M 48.70M
Net debt -374.60M -179.30M -544.90M -576.40M -437.30M
Short term debt 22.70M 18.80M 151.70M 18.20M 53.50M
Short long term debt - - 134.00M 2.20M 44.20M
Short long term debt total 416.70M 305.30M 309.00M 317.90M 325.30M
Other stockholder equity -1112.20M -1035.00M -517.40M -138.70M 19.50M
Property plant equipment 1843.40M 1715.80M 1512.50M 1158.30M 1057.50M
Total current assets 1978.20M 1538.10M 1936.40M 1919.50M 1742.00M
Long term investments 212.30M 202.10M 210.00M 204.90M 207.70M
Net tangible assets - - - 2559.20M 2067.30M
Net receivables 574.40M 552.50M 512.00M 507.40M 489.00M
Long term debt 202.80M 202.60M 72.80M 206.70M 208.80M
Inventory 443.90M 377.00M 434.70M 414.80M 378.40M
Accounts payable 253.70M 239.30M 242.40M 215.40M 232.20M
Accumulated other comprehensive income -105.50M -258.10M -143.80M -183.00M -159.60M
Common stock total equity - - - 18.80M 18.80M
Retained earnings total equity - - - 2987.80M 2456.70M
Treasury stock - - - -370.90M -229.50M
Non currrent assets other 80.10M 74.30M 21.30M 38.40M 55.90M
Non current assets total 2291.90M 2105.40M 1893.10M 1697.30M 1571.80M
Capital lease obligations 118.30M 99.70M 102.20M 109.00M 72.30M
Long term debt total 202.80M 204.70M 72.80M 206.70M 208.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -378.70M -354.70M -288.20M -253.10M
Change to liabilities - - - -2.80M 16.80M
Total cashflows from investing activities -285.90M -378.70M -368.70M -288.20M -253.10M
Net borrowings -1.10M -27.60M -2.40M -45.50M -2.20M
Total cash from financing activities -185.10M -622.60M -459.60M -293.60M -168.10M
Change to operating activities - - - 76.70M -0.60M
Net income 493.70M 492.70M 593.40M 585.90M 661.80M
Change in cash 306.70M -369.30M -40.40M 131.70M 147.10M
Begin period cash flow 484.60M 853.90M 894.30M 762.60M 615.50M
End period cash flow 791.30M 484.60M 853.90M 894.30M 762.60M
Total cash from operating activities 754.80M 653.40M 776.50M 724.00M 584.00M
Depreciation 168.60M 155.40M 137.30M 120.60M 122.30M
Other cashflows from investing activities 0.00M -1.70M -6.70M -3.60M 0.30M
Dividends paid 61.20M 59.10M 57.00M -54.10M -51.10M
Change to inventory -62.80M 42.00M -13.50M -49.80M -86.50M
Change to account receivables 6.90M -58.80M 4.00M -35.60M -123.50M
Sale purchase of stock -134.00M -566.60M -451.20M -222.20M -151.90M
Other cashflows from financing activities -7.00M 30.70M 50.90M 27.00M 37.10M
Change to netincome - - - 29.70M -19.70M
Capital expenditures 285.90M 377.00M 362.00M 284.60M 253.40M
Change receivables - - - -35.60M -123.50M
Cash flows other operating - - - 76.00M 12.80M
Exchange rate changes - - - - -15.70M
Cash and cash equivalents changes - - - 142.20M 147.10M
Change in working capital 79.80M 2.90M -20.40M -11.50M -193.80M
Stock based compensation 23.80M 18.70M 23.30M 23.70M 37.50M
Other non cash items 2.60M -16.30M 5.40M 36.10M -0.90M
Free cash flow 468.90M 276.40M 414.50M 439.40M 330.60M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WST
West Pharmaceutical Services Inc		 8.69
2.17%		 408.50 46.73 36.50 7.72 8.36 7.48 28.28
ISRG
Intuitive Surgical Inc		 5.32
1.17%		 458.12 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 2.75
1.29%		 215.85 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.44
0.41%		 107.31 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 0.08
0.04%		 211.96 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

530 Herman O. West Drive, Exton, PA, United States, 19341-1147

610 594 2900

https://www.westpharma.com

10800

Name Title Year Born
Mr. Eric M. Green Chair, Pres & CEO 1970
Mr. Bernard J. Birkett Sr. VP and Chief Financial & Operations Officer 1969
Mr. Silji Abraham Sr. VP & Chief Technology Officer 1972
Ms. Kimberly Banks MacKay Sr. VP, Gen. Counsel & Company Sec. 1966
Mr. Chad R. Winters VP, Chief Accounting Officer & Corp. Controller 1979
Dr. Quintin J. Lai C.F.A., Ph.D. VP of Strategy & Investor Relations 1967
Michele Polinsky VP of Global Communications NA
Mr. Robert Segura VP of Corp. Devel. NA
Ms. Annette F. Favorite Chief HR Officer & Sr. VP 1965
Mr. Richard D. Luzzi Sr. VP of HR 1952

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…